Enlivex Therapeutics is a clinical-stage company focused on macrophage reprogramming.

The company intends to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, sepsis, COVID-19, and other indications.The company's most advanced product candidate, Allocetra, was developed for the reprogramming of diseased macrophages in patients with sepsis or COVID-19, and has demonstrated positive safety, tolerability, and efficacy in several clinical trials.

In March 2019, the company announced the completion of its merger with Tel Aviv-headquartered Bioblast Pharma.

Following the reverse merger, Enlivex became a subsidiary of Bioblast, which was renamed Enlivex Therapeutics.